Advertisement
Screener

Lunai Bioworks Inc. (LNAI) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

Lunai Bioworks Inc. Research and Development Expense

Lunai Bioworks Inc. (LNAI) reported Research and Development Expense of $15.95 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-15

  • Lunai Bioworks Inc. research and development expense for the quarter ending 2026-03-31 was $15.95K.
  • Lunai Bioworks Inc. research and development expense for the quarter ending 2025-12-31 was $45.87K, a 71.52% decline year-over-year.
  • Lunai Bioworks Inc. research and development expense for the quarter ending 2025-09-30 was $24.41K, a 93.74% decline year-over-year.
  • Lunai Bioworks Inc. research and development expense for the quarter ending 2024-12-31 was $161.08K, a 74.04% decline year-over-year.
  • Lunai Bioworks Inc. research and development expense for fiscal 2025 was $537.43K, a 80.16% decline from fiscal 2024.
  • Lunai Bioworks Inc. research and development expense for fiscal 2024 was $2.71M, a 34.97% decline from fiscal 2023.
  • Lunai Bioworks Inc. research and development expense for fiscal 2023 was $4.17M, a 50.25% decline from fiscal 2022.
  • Lunai Bioworks Inc. research and development expense for fiscal 2022 was $8.37M, a 46.74% decline from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2026-03-31$15.95K
10-Q · filed 2026-05-15
$61.82K
derived: sum of 2 quarters · filed 2026-05-15
$86.23K
10-Q · filed 2026-05-15
2025-12-31$45.87K
10-Q · filed 2026-02-17
$70.28K
10-Q · filed 2026-02-17
2025-09-30$24.41K
10-Q · filed 2025-11-14
2025-06-30$537.43K
10-K · filed 2025-09-29
2024-12-31$161.08K
10-Q · filed 2026-02-17
$551.27K
10-Q · filed 2026-02-17
$985.78K
derived: sum of 3 quarters · filed 2026-02-17
$2.07M
derived: sum of 4 quarters · filed 2026-02-17
2024-09-30$390.19K
10-Q · filed 2025-11-14
$824.70K
derived: sum of 2 quarters · filed 2025-11-14
$1.91M
derived: sum of 3 quarters · filed 2025-11-14
$2.53M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30$434.51K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-09-29
$1.52M
derived: sum of 2 quarters · filed 2025-09-29
$2.14M
derived: sum of 3 quarters · filed 2025-09-29
$2.71M
10-K · filed 2025-09-29
2024-03-31$1.09M
10-Q/A · filed 2025-02-19
$1.71M
derived: sum of 2 quarters · filed 2025-02-19
$2.27M
10-Q/A · filed 2025-02-19
$3.27M
derived: sum of 4 quarters · filed 2025-02-19
2023-12-31$620.52K
10-Q · filed 2025-02-19
$1.19M
10-Q · filed 2025-02-19
$2.18M
derived: sum of 3 quarters · filed 2025-02-19
$2.42M
derived: sum of 4 quarters · filed 2025-02-19
2023-09-30$566.64K
10-Q/A · filed 2025-02-19
$1.56M
derived: sum of 2 quarters · filed 2025-02-19
$1.80M
derived: sum of 3 quarters · filed 2025-02-19
$2.13M
derived: sum of 4 quarters · filed 2025-02-19
2023-06-30$994.73K
derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2025-02-19
$1.23M
derived: sum of 2 quarters · filed 2025-02-19
$1.56M
derived: sum of 3 quarters · filed 2025-02-19
$4.17M
10-K/A · filed 2025-02-19
2023-03-31$239.14K
10-Q/A · filed 2025-02-19
$565.10K
derived: sum of 2 quarters · filed 2025-02-19
$3.17M
10-Q/A · filed 2025-02-19
$4.94M
derived: sum of 4 quarters · filed 2025-02-19
2022-12-31$325.96K
10-Q · filed 2024-02-14
$2.93M
10-Q · filed 2024-02-14
$4.70M
derived: sum of 3 quarters · filed 2024-02-14
$5.91M
derived: sum of 4 quarters · filed 2024-02-14
2022-09-30$2.61M
10-Q · filed 2023-11-14
$4.37M
derived: sum of 2 quarters · filed 2023-11-14
$5.59M
derived: sum of 3 quarters · filed 2023-11-14
$7.92M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$1.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-02
$2.98M
derived: sum of 2 quarters · filed 2023-10-02
$5.32M
derived: sum of 3 quarters · filed 2023-10-02
$8.37M
10-K · filed 2023-10-02
2022-03-31$1.21M
10-Q · filed 2023-05-12
$3.55M
derived: sum of 2 quarters · filed 2023-05-12
$6.61M
10-Q · filed 2023-05-12
$18.75M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31$2.34M
10-Q · filed 2023-03-09
$2.14M
10-Q · filed 2022-02-14
$5.39M
10-Q · filed 2023-03-09
$5.15M
10-Q · filed 2022-02-14
$17.54M
derived: sum of 3 quarters · filed 2023-03-09
$18.66M
derived: sum of 4 quarters · filed 2023-03-09
2021-09-30$3.06M
10-Q · filed 2023-03-07
$3.01M
10-Q · filed 2021-11-15
$15.20M
derived: sum of 2 quarters · filed 2023-03-07
$16.32M
derived: sum of 3 quarters · filed 2023-03-07
$17.65M
derived: sum of 4 quarters · filed 2023-03-07
2021-06-30$12.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
$13.26M
derived: sum of 2 quarters · filed 2023-02-27
$14.60M
derived: sum of 3 quarters · filed 2023-02-27
$15.72M
10-K · filed 2023-02-27
$15.54M
10-K · filed 2021-09-24
2021-03-31$1.12M
10-Q · filed 2022-05-13
$1.08M
10-Q · filed 2021-05-17
$2.45M
derived: sum of 2 quarters · filed 2022-05-13
$3.57M
10-Q · filed 2022-05-13
$3.46M
10-Q · filed 2021-05-17
$4.81M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31$1.33M
10-Q · filed 2022-02-14
$2.38M
10-Q · filed 2022-02-14
$3.69M
derived: sum of 3 quarters · filed 2022-02-14
$6.00M
derived: sum of 4 quarters · filed 2022-02-14
2020-09-30$1.05M
10-Q · filed 2021-11-15
$2.36M
derived: sum of 2 quarters · filed 2021-11-15
$4.66M
derived: sum of 3 quarters · filed 2021-11-15
$5.22M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$1.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24
$3.61M
derived: sum of 2 quarters · filed 2021-09-24
$4.17M
derived: sum of 3 quarters · filed 2021-09-24
$4.69M
10-K · filed 2021-09-24
2020-03-31$2.31M
10-Q · filed 2021-05-17
$2.87M
derived: sum of 2 quarters · filed 2021-05-17
$3.39M
10-Q · filed 2021-05-17
$3.87M
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31$561.47K
10-Q · filed 2021-02-16
$1.08M
10-Q · filed 2021-02-16
$1.57M
derived: sum of 3 quarters · filed 2021-02-16
$2.30M
derived: sum of 4 quarters · filed 2021-02-16
2019-09-30$520.19K
10-Q · filed 2020-11-12
$1.01M
derived: sum of 2 quarters · filed 2020-11-12
$1.74M
derived: sum of 3 quarters · filed 2020-11-12
$2.52M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$485.33K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-23
$1.22M
derived: sum of 2 quarters · filed 2020-09-23
$2.00M
derived: sum of 3 quarters · filed 2020-09-23
$2.50M
10-K · filed 2020-09-23
2019-03-31$730.25K
10-Q · filed 2020-05-11
$1.52M
derived: sum of 2 quarters · filed 2020-05-11
$2.01M
10-Q · filed 2020-05-11
$2.12M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$788.97K
10-Q · filed 2020-02-10
$1.28M
10-Q · filed 2020-02-10
$1.39M
derived: sum of 3 quarters · filed 2020-02-10
$1.53M
derived: sum of 4 quarters · filed 2020-02-10
2018-09-30$493.56K
10-Q · filed 2019-11-13
$598.98K
derived: sum of 2 quarters · filed 2019-11-13
$736.89K
derived: sum of 3 quarters · filed 2019-11-13
$956.86K
derived: sum of 4 quarters · filed 2019-11-13
2018-06-30$105.42K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-30
$243.34K
derived: sum of 2 quarters · filed 2019-09-30
$463.31K
derived: sum of 3 quarters · filed 2019-09-30
$616.96K
10-K · filed 2019-09-30
2018-03-31$137.92K
10-Q · filed 2019-05-16
$357.88K
derived: sum of 2 quarters · filed 2019-05-16
$511.54K
10-Q · filed 2019-05-16
$527.12K
derived: sum of 4 quarters · filed 2019-05-16
2017-12-31$219.97K
10-Q · filed 2019-02-13
$373.62K
10-Q · filed 2019-02-13
$389.20K
derived: sum of 3 quarters · filed 2019-02-13
$405.49K
derived: sum of 4 quarters · filed 2019-02-13
2017-09-30$153.65K
10-Q · filed 2018-11-14
$169.23K
derived: sum of 2 quarters · filed 2018-11-14
$185.52K
derived: sum of 3 quarters · filed 2018-11-14
$199.31K
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30$15.58K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-01
$31.87K
derived: sum of 2 quarters · filed 2018-10-01
$45.66K
derived: sum of 3 quarters · filed 2018-10-01
$62.76K
10-K · filed 2018-10-01
2017-03-31$16.29K
10-Q · filed 2018-05-15
$30.08K
derived: sum of 2 quarters · filed 2018-05-15
$47.18K
10-Q · filed 2017-05-15
$236.03K
derived: sum of 4 quarters · filed 2018-05-15
2016-12-31$13.79K
10-Q · filed 2018-02-09
$30.89K
10-Q · filed 2018-02-09
$219.75K
derived: sum of 3 quarters · filed 2018-02-09
$455.67K
derived: sum of 4 quarters · filed 2018-02-09
2016-09-30$17.10K
10-Q · filed 2017-11-20
$205.96K
derived: sum of 2 quarters · filed 2017-11-20
$441.88K
derived: sum of 3 quarters · filed 2017-11-20
$719.53K
derived: sum of 4 quarters · filed 2017-11-20
2016-06-30$188.85K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-11-20
$424.78K
derived: sum of 2 quarters · filed 2017-11-20
$702.43K
derived: sum of 3 quarters · filed 2017-11-20
$804.19K
10-K · filed 2017-11-20
2016-03-31$235.93K
10-Q · filed 2017-05-15
$513.58K
derived: sum of 2 quarters · filed 2017-05-15
$615.33K
10-Q · filed 2017-05-15
$2.09M
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31$277.65K
10-Q · filed 2017-02-14
$379.41K
10-Q · filed 2017-02-14
$1.85M
derived: sum of 3 quarters · filed 2017-02-14
$2.00M
derived: sum of 4 quarters · filed 2017-02-14
2015-09-30$101.76K
10-Q · filed 2016-11-14
$1.58M
derived: sum of 2 quarters · filed 2016-11-14
$1.73M
derived: sum of 3 quarters · filed 2016-11-14
2015-06-30$1.47M
derived: 10-K 6 month − 10-Q 3 month · filed 2016-09-28
$1.63M
10-K · filed 2016-09-28
2015-03-31$151.81K
10-Q · filed 2016-05-13
$151.81K
10-Q · filed 2016-05-13
2014-09-30$143.15K
10-Q · filed 2014-11-13
$221.55K
10-Q · filed 2014-11-13
2013-09-30$0.00
10-Q · filed 2014-11-13
$0.00
10-Q · filed 2014-11-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Cingulate Inc. (CING)United States$0.073B-2.64
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39